COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

202403_BB_Best Practices_823x462.jpg

Best Practices for Promoting Compounded Preparations

Below, we outline key guidelines to help ensure your promotional efforts remain ethical, compliant and effective.

Guidelines for Promotional Content

  1. Focus on Facts
    We encourage members to share factual information about the technical aspects of compounded preparations and ingredients, supported by published articles, case studies and technical reports. Any use of patient testimonials should be focused on aspects of service, such as customer satisfaction, personalization of care or the professionalism of staff, rather than the effects of the compounded medication itself.
  2. Communicating with Care
    When discussing the effects of compounded preparations, it's essential to avoid claims about treating, curing or mitigating diseases unless backed by substantial evidence and in compliance with FDA guidelines. Similarly, steer clear of suggesting that a preparation is "safe" or "effective" for any condition. In all communications, prominently include the disclaimer: “The FDA does not review any compounded medication for safety or efficacy.”
  3. Avoid Comparing Compounded Preparations to FDA-Approved Commercial Drugs
    Avoid all direct comparisons between compounded medications and FDA-approved drugs in marketing materials. Instead, focus on the unique aspects of compounded medications, such as their ability to be tailored to meet individual patient needs when commercially available options are not suitable.

Our Commitment to Compliance

PCCA is committed to upholding the highest compliance standards with regulatory guidelines, recognizing the complexity of pharmaceutical compounding and marketing. These recommendations are a starting point; we strongly encourage engaging with legal counsel who specialize in FDA regulations and pharmacy law to regularly review your marketing materials. This proactive approach ensures your promotional efforts reflect the latest standards and practices.

Related Posts


  • 20240207_BG_Working Methylene Blue_823x462.jpg

    Working with Methylene Blue: Best Practices for Compounding and Cleanup

    As compounders, we work with a variety of active pharmaceutical ingredients (APIs), some of which are more challenging to compound than others. Compounding with methylene blue as an API has risen due to emerging research for a variety of clinical applications. However, methylene blue can be intimidating to compound due to its intense blue color, which may stain costly lab equipment, countertops and other materials. Discover some useful techniques that can ease the sometimes stressful process of working with this vibrant API.
  • SEO_and_Best_Practices_for_Pharmacy_Websites.jpg

    SEO and Best Practices for Pharmacy Websites

    Seth Humble is PCCA's SEO Analyst. In this article he provides best practices and a clear path for pharmacy owners and pharmacy marketers who need help understanding how Search Engine Optimization (SEO) works, and how they can implement it themselves or through their website developer.
  • The_Role_of_Surfactants_in_Compounded_Preparations.jpg

    The Role of Surfactants in Compounded Preparations

    Surfactants are versatile ingredients in pharmacy compounding. Four PCCA experts explain what they are and list many of the ones that are used commonly, including their important characteristics to help you determine which surfactants to use in different situations.
  • Choosing_an_Appropriate_Gelling_Agent_for_Your_Compounded_Preparation.jpg

    Choosing an Appropriate Gelling Agent for Your Compounded Preparation

    Courtaney Davis and Stacey Lemus, both PCCA formulation specialists discuss the best practices to consider when selecting a gelling agent for your compounded preparation.
  • Proposed_Changes_to_USP_797.jpg

    Proposed Changes to USP 797

    Matt Martin points out the most significant change in the newly proposed version of USP Chapter 797 as well as the cascading effects it has on the guidelines. He also explains the process for the proposed version to become official and what compounding pharmacies and other stakeholders should do about it now.
  • image (1).png

    Factors That Affect the Stability of Compounded Medications

    One of PCCA's clinical compounding pharmacists highlights the most critical stability factors listed in USP Chapter 1191 as well as the most common signs of instability in compounded medications.
avoid claims in compounded medications, best marketing practices, FDA guidance for promoting compounded medications, marketing compounded preparations, promoting compound, what to say when promoting compounded medicines


Comments are closed.